"Have we done everything we can for this person?"

The spirit of that question lives in the hopes of this website which embodies the vision of Sidney Baker, to whom that question was posed repeatedly in 1959 in the valley of Katmandu by Dr. Edgar Miller, with whom Sid apprenticed before going to Yale medical school.

After graduation and specialty training in Pediatrics he joined the Faculty as Assistant Professor of Pediatrics and Medical Computer Science. With his mentor, Shannon Brunjes, MD, Dr. Baker focused on how information technology could empower us to answer Dr. Miller's question. During nearly four decades of medical practice Dr. Baker served as Director of the Gesell Institute of Human Development where he co-authored two of the Gesell books on Child Development, began his interest in autism and friendship with Bernard Rimland, PhD founder of Autism Research Institute (ARI) and The Autism Society of America.

Dr. Baker is the author of Detoxification and Healing, The Circadian Prescription and, with Jon Pangborn, PhD, Autism: Effective Biomedical Treatments. In 2000 he founded Medigenesis.com, which is based on the proven capacity of structured clinical data to capture the threads of individuality into a tapestry in which we can see otherwise invisible patterns. Honored for his contribution to the development of integrative medicine, he has practiced and published the principles that underlie effective listening, recording, retrieving and reporting the details that allow us to see and present ourselves as individuals, regain balance and retain the control that favors healing of chronic illness. His hope is that this website will help you answer Dr. Miller's question and the much easier one: "What are the best treatment options for my child?"

As Executive Director, Tain Hsia brings to Autism360 over 15 years of experience in finance and central banking. Prior to joining Autism360, Ms. Hsia held various roles in research, strategy and market analysis at Merrill Lynch, Lehman Brothers, Barclays, Nomura Securities International and the Federal Reserve Bank of New York. Ms. Hsia holds a M.B.A. from Columbia Business School and a B.A. in economics from Barnard College.

Three years ago Ms. Hsia met a boy whose struggle with ASD touched her heart. Two years ago her oldest daughter, Gillian, was diagnosed with severe gluten intolerance. The treatments that Dr. Baker and his colleagues recommended for Gillian to manage her chronic condition not only transformed the way Ms. Hsia views medicine but also changed the way she sees the world. Ms. Hsia is honored for the opportunity to help families navigate the overwhelming amount of information in treating ASD.

Sudhir Gupta received his medical and doctorate degrees from the King George's Medical College. He was a Teaching Faculty Fellow at the Tufts University School of Medicine, Boston and a Visiting Fellow in Medicine at the College of Physicians and Surgeons, Columbia University, New York. He then joined Memorial Sloan Kettering Cancer Center and Cornell University Medical College, New York and in record time rose to the rank of an Associate Professor of Medicine and Immunology. In 1982, he moved to the University of California, Irvine as a Professor of Medicine and Chief of Immunology. Currently he is a highest ranking Professor of Medicine, Pathology & Laboratory Medicine, and Microbiology & Molecular Genetics, and the Chief of the Division of Basic and Clinical Immunology at the University of California, Irvine. He is the Program Director of the Allergy and Immunology Training Program and the Director of the Jeffery Modell Center for Primary Immunodeficiency at the University of California, Irvine. He also serves as the Director of Scientific Development, The Sass Foundation for Medical Research, New York.

Dr. Gupta is board certified in Clinical Immunology by the Royal College of Physicians and Surgeons of Canada, and both in Allergy and Immunology and Diagnostic Laboratory Immunology by the American Boards of Allergy and Immunology. He is a Fellow of number of scientific societies including Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine, London, American College of Rheumatology and others. He has received numerous awards, including Arthur Manzel Award from the College of Physicians and Surgeons, Columbia University; Lifetime Achievement Award from the J.M. Foundation, New York, Outstanding Scientist Award in Medical Sciences by FIA, Most Distinguished Physician, Researcher, and Teacher Awards from the American Association of Physicians from India. Dr. Gupta has been Visiting Professor at various universities around the globe and has delivered numerous Oration lectures. The Board of Regents of the American College of Physicians conferred upon Dr. Gupta its highest honor, the Mastership of the American College of Physicians. He is a recipient of the prestigious Ranbaxy Science Foundation Award in Medical Sciences for his contributions to the T cell biology in human aging. Dr. Gupta was presented to Her Majesty the Queen Elizabeth and Prince Philip at a special ceremony of the Royal Society of Medicine, London. He also served as a Scientific Advisor to the late Prime Minister Indira Gandhi.

Dr. Gupta has served on numerous important National and International committees, including Committees of the National Institutes of Health, Food and Drug Administration, and Advisory committee of the World Health Organization. Currently, he is serving on Aging System and Geriatric Study Section of the National Institute of aging, NIH. Dr. Gupta has served and serving as a member of the Editorial/Advisory Boards of more than thirty national and international scientific journals. He is also the Founding and current Editor in Chief of the Journal of Clinical Immunology (since 1980).

Dr. Sudhir Gupta is internationally known for his important contributions in the field of cellular and molecular immunology as it relates to AIDS, cancer research, aging, autism, primary immunodeficiency diseases, and aging. Some of his landmark and original contributions have been published in high impact journals like Nature, Science, Proceedings of the National Academy of Sciences, Journal of Experimental Medicine, Journal of Clinical Investigation, Journal of Immunology, New England Journal of Medicine, Blood, Genes and Immunity, Nature Cardiovascular. etc.

He has published more than 500 scientific papers, invited reviews, and book chapters. He has edited 23 books in various areas of cellular, molecular and applied immunology. He has trained more than 65 physicians and scientist from all over the globe. Many of his trainees are now Professors, Chair of the Departments, and Dean at major Universities around the globe.

Doreen Granpeesheh is the Founder and Executive Director of the Center for Autism and Related Disorders (CARD) and the Founder and President of the Board of Autism Care and Treatment Today (ACT Today). Dr. Granpeesheh received her Ph.D. in Psychology from UCLA and is licensed by the Medical Board of California and the Texas and Arizona State Boards of Psychologists.

Dr. Granpeesheh holds a Certificate of Professional Qualification in Psychology from the Association of State and Provincial Psychology Boards, is a Board Certified Behavior Analyst and has been providing behavioral therapy for children with autism since 1979.

Dr. Granpeesheh is first Vice Chair of the National Board of Directors of the Autism Society of America, member of the Autism Human Rights and Discrimination Initiative Steering Committee and on the Oversight Committee of the Department of Developmental Disabilities for the State of Arizona.

Professor of Biological Chemistry, Head of Department of Biomolecular Medicine, Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College London. Professor Nicholson obtained his BSc from Liverpool University (1977) and his PhD from London University (1980) working on the application of analytical electron microscopy and the applications of energy dispersive X Ray microanalysis in molecular toxicology and inorganic biochemistry. His current research interests include novel NMR spectroscopy, mass spectrometry and chemometric approaches to understanding the molecular basis of disease and toxic processes, and extended genome/superorganism biochemistry.

He was appointed Lecturer in Chemistry (Birkbeck College, London University, 1981-83) and Lecturer in Experimental Pathology at The London School of Pharmacy (1983-85) returning to Birkbeck as a Senior Lecturer in Chemistry, then Reader (1989) and Professor of Biological Chemistry (1992). In 1998 he became Head of Biological Chemistry at Imperial College London and since 2006 he has been the Head of the Department of Biomolecular Medicine (2006) at Imperial. Professor Nicholson is the author of over 600 scientific papers and articles on the development and application of novel spectroscopic and chemometric approaches to the investigation of disturbed metabolic processes in complex organisms.

His research has been recognised by awards such as: The Royal Society of Chemistry (RSC) SAC Silver (1992) and SAC Gold (1997) Medals for Analytical Chemistry; The UK Chromatographic Society Jubilee Silver Medal (1994); Pfizer Prize for Chemical and Medicinal Technology (2002); RSC Silver Medal for Chemical Biology (2003); and the Pfizer Global Research Chemistry Prize (2006), the RSC Theophilus Redwood Lectureship (2008) and the RSC Interdisciplinary Prize (2008). Professor Nicholson is a Fellow of the Royal Society of Chemistry, The Royal Society of Pathologists, a Fellow of the Institute of Biology and a Fellow of the British Toxicological Society. He currently holds honorary professorships at 6 Universities and 2 Professorships at the Chinese Academy of Sciences, and is on the editorial board of 8 major scientific journals. He is a consultant for many pharmaceutical/healthcare companies in the UK, Europe and the USA and is a founder director of Metabometrix, an Imperial College spin-off company specializing in molecular phenotyping, clinical diagnostics and toxicological screening via metabonomics and metabolomics.

S. Jill James is a Professor in the Department of Pediatrics, Section of Developmental Disabilities, and the Director of the Metabolic Genomics Laboratory at the Arkansas Children's Hospital Research Institute. She received her B.S. degree in Biology from Mills College, and her Ph.D. degree in Nutritional Biochemistry from UCLA. Her research career has been devoted to defining gene-nutrient interactions that increase susceptibility to cancer, Down syndrome, birth defects, and most recently, autism.

She has published over 130 peer-reviewed papers and recently received the American Society for Nutritional Sciences award for innovative research contributing to the understanding of human nutrition. She is currently funded by a 5 year NIH grant entitled "Metabolic biomarkers of autism: predictive potential and genetic susceptibility", a grant for the Department of Defense entitled "Autism as a vulnerability phenotype" and a grant from Autism Speaks for the "Arkansas Autism Treatment Network".

Mark Hyman is Vice-Chair of the Board of Directors and faculty of the Institute for Functional Medicine and was awarded the 2009 Linus Paul Award for leadership in Functional Medicine. He is on the Board of Directors of the Center for Mind Body Medicine in Washington DC, and on the Board of Advisors and faculty for the Food as Medicine training program, and Memhet Oz's HealthCorps. He is a family physician, four times New York Times bestselling author and a lecturer. Dr. Hyman has become an internationally recognized leader in the field of functional medicine. He graduated with a B.A. from Cornell University, and received his medical degree from the Ottawa University School of Medicine. He completed his residency at University of San Francisco's program in Family Medicine at the Community Hospital of Santa Rosa.

Dr. Hyman is editor of Alternative Therapies in Health and Medicine, a premiere peer-reviewed professional journal in the fields of integrative medicine and alternative medicine; and is the Medical Editor Natural Solutions, which is dedicated to helping consumers improve their health and the quality of their lives. He is on the editorial board of Integrative Medicine: A Clinician's Journal. Dr. Hyman has testified regarding health promotion and wellness for the White House Commission on Complementary and Alternative Medicine and has consulted with Surgeon General Richard H. Carmona on diabetes prevention. He had testified before the Senate Working Group on Health Care Reform on Functional Medicine.

Dr. Hyman was co-Medical Director for eight years at Canyon Ranch Lenox, one of the world's leading health resorts; co-authored the New York Times bestseller Ultraprevention: The 6-week Program That Will Make You Healthy for Life (Scribner), winner of the Books for a Better Life Award, which honors the best self-improvement books published each year; and wrote the New York Times bestseller UltraMetabolism: The Simple Plan for Automatic Weight Loss for which Dr. Hyman also created a public television special. His latest book, and companion PBS special, The UltraMind Solution, a comprehensive approach for addressing the causes of mental illness and cognitive disorders, was released in January 2009. Dr. Hyman will serve on the Scientific Advisory Committee and provide expertise on functional medicine in new research program at Harvard Medical School.

For more information please visit, www.ultrawellnesscenter.com, or www.ultrawellness.com or www.ultramind.com

To receive Dr. Hyman's weekly blog go to www.ultrawellness.com/blog

Mark Noble holds professorships in Neurology, Genetics and Neurobiology and Anatomy at University of Rochester School of Medicine, New York and is Director of the University of Rochester Stem Cell and Regenerative Medicine Institute and Co-Director of the New York State Center of Research Excellence for Spinal Injury Research. He has been the recipient of research funding from a wide variety of institutes and foundations (including the National Institute of Neurological Diseases and Stroke (NIH), the National Cancer Institute (NIH), the National Institute of Aging (NIH), the National Institute of Environmental Health Sciences (NIH), the National Institute for Child Health and Development (NIH), the Department of Defense, Autism Speaks, the Komen Foundation for the Cure, Hunter's Hope Foundation, the New York State Spinal Cord Injury Research Program and the New York State Stem Cell Research Program). Dr. Noble also serves, or has served, on multiple review boards for the NIH and for private foundations (including the James F. McDonnell Foundation, Autism Speaks, Katie's Kids for the Cure, the Komen Foundation for the Cure and the Ontario Cancer Institute). He is an inventor on 11 filed or pending patents and has consulted for multiple pharmaceutical and biotechnology companies. He also was a member of the founding scientific advisory board of Acorda Therapeutics, Inc., a biotechnology company focused on the treatment of neurological disease. He is co-author of over 140 scientific publications.

Dr. Noble received his B.A. (Biology and Philosophy) from Franklin & Marshall College in 1971 and his Ph.D. (Genetics) from Stanford University in 1977. He then moved to University College London as a postdoctoral fellow, with subsequent appointments at the Institute of Neurology (Queen Square London; Honorary Lecturer), Ludwig Institute for Cancer Research (Laboratory Head and eventual Full Member), University College London (Professor of Cellular and Developmental Biology), Huntsman Cancer Institute (University of Utah, Salt Lake City; Professor of Oncology). He joined the faculty of the University of Rochester in 2000.

Research:
Mark Noble is one of the pioneers of stem cell research. His contributions to the field date back to 1983 when, as a member of a team of researchers in London, he co-discovered the first precursor cell isolated from the central nervous system (CNS). His laboratory was then the first to identify means of growing these cells in tissue culture, means of enabling expansion sufficient for carrying out repair, and the first to the obtain cell repair in the damaged central nervous system through transplantation of purified populations of precursor cells. During this period, Dr. Noble's laboratory also conducted leading research on the properties of progenitor cells of the adult central nervous system, oncogene cooperation and cellular function, use of 1H-NMR spectroscopy to identify different cell types and tumors, development of novel approaches to the isolation of cell lines from multiple tissues of the body and on the role of intracellular redox balance in the modulation of cell function.

Dr. Noble and his associates currently work in multiple areas of stem cell research and related fields. Current fields of activity include:

1. Cell discovery
2. Glial progenitor cells and the development of glial repair strategies
   1. Oligodendrocyte replacement and repair of demyelinating damage
   2. Development of astrocyte transplantation therapies and the importance of pre-differentiation as a strategy for optimizing CNS repair
   3. Causing harm by transplanting the wrong cell type
3. Precursor cell dysfunction as a critical component of disease pathogenesis: Precursor cell diseases as a major clinical problem
4. Bystander diseases: Astrocytic dysfunction as a causal mechanism in neurological disease
5. Chemotherapy-induced damage to the CNS as a precursor cell disease
   1. CNS precursor cells are as or more vulnerable than cancer cells to multiple chemotherapeutic agents
   2. Treatment with 5-fluorouracil (5-FU) causes a syndrome of delayed CNS degeneration
6. Cellular and molecular analysis of glioma generation and biology
7. Precursor cell physiology: Regulation of development, signaling and disease by small changes in intracellular redox status
8. Toxicant-mediated disruption of progenitor cell and neuronal function
9. Toxicant-mediated effects on signaling pathway function, and the discovery of the redox/Fyn/c-Cbl pathway as a central regulator of precursor cell function
10. Quantitative analysis of precursor cell biology
11. Stem cell ethics and the interaction between scientists and the public

Full information on Dr. Noble's research activities can be found at www.urmc.rochester.edu/GEBS/faculty/Mark_Noble.htm